Cargando…

Highly Specific Epigenome Editing by CRISPR/Cas9 Repressors for Silencing of Distal Regulatory Elements

Epigenome editing with the CRISPR/Cas9 platform is a promising technology to modulate gene expression to direct cell phenotype and to dissect the causal epigenetic mechanisms of gene regulation. Fusions of the nuclease-inactive dCas9 to the KRAB repressor (dCas9-KRAB) can silence target gene express...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thakore, Pratiksha I., D’Ippolito, Anthony M, Song, Lingyun, Safi, Alexias, Shivakumar, Nishkala K., Kabadi, Ami M., Reddy, Timothy E., Crawford, Gregory E., Gersbach, Charles A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666778/ https://www.ncbi.nlm.nih.gov/pubmed/26501517 http://dx.doi.org/10.1038/nmeth.3630

Ejemplares similares

Epigenome editing by a CRISPR/Cas9-based acetyltransferase activates genes from promoters and enhancers
por: Hilton, Isaac B., et al.
Publicado: (2015)

CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome
por: Klann, Tyler S., et al.
Publicado: (2017)

RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors
por: Thakore, Pratiksha I., et al.
Publicado: (2018)

Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations that Cause Duchenne Muscular Dystrophy
por: Ousterout, David G., et al.
Publicado: (2015)

Targeted genome and epigenome editing using engineered TALE and CRISPR/Cas9 technologies
por: Gersbach, Charles A
Publicado: (2014)

Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients
por: Ousterout, David G, et al.
Publicado: (2013)

CRISPR-Mediated Epigenome Editing
por: Enríquez, Paul
Publicado: (2016)

RNA-guided gene activation by CRISPR-Cas9-based transcription factors
por: Perez-Pinera, Pablo, et al.
Publicado: (2013)

Transgenic mice for in vivo epigenome editing with CRISPR-based systems
por: Gemberling, Matthew P., et al.
Publicado: (2021)

Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector
por: Kabadi, Ami M., et al.
Publicado: (2014)

Correction of Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients Through Genomic Excision of Exon 51 by Zinc Finger Nucleases
por: Ousterout, David G, et al.
Publicado: (2015)

Enhanced MyoD-Induced Transdifferentiation to a Myogenic Lineage by Fusion to a Potent Transactivation Domain
por: Kabadi, Ami M., et al.
Publicado: (2014)

Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators
por: Polstein, Lauren R., et al.
Publicado: (2015)

A CRISPR/Cas9-Based System for Reprogramming Cell Lineage Specification
por: Chakraborty, Syandan, et al.
Publicado: (2014)

Concurrent genome and epigenome editing by CRISPR-mediated sequence replacement
por: Alexander, Jes, et al.
Publicado: (2019)

Predicting the effect of CRISPR-Cas9-based epigenome editing
por: Batra, Sanjit Singh, et al.
Publicado: (2023)

An Overview of the CRISPR-Based Genomic- and Epigenome-Editing System: Function, Applications, and Challenges
por: Bozorg Qomi, Saeed, et al.
Publicado: (2019)

Expanded CAG/CTG repeats resist gene silencing mediated by targeted epigenome editing
por: Yang, Bin, et al.
Publicado: (2021)

Incomplete MyoD-induced transdifferentiation is associated with chromatin remodeling deficiencies
por: Manandhar, Dinesh, et al.
Publicado: (2017)

Glucocorticoid receptor recruits to enhancers and drives activation by motif-directed binding
por: McDowell, Ian C., et al.
Publicado: (2018)

CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review
por: Syding, Linn Amanda, et al.
Publicado: (2020)

Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum
por: Frank, Christopher L., et al.
Publicado: (2015)

DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A
por: Huang, Yung-Hsin, et al.
Publicado: (2017)

Improved tetracycline repressors for gene silencing in mycobacteria
por: Klotzsche, Marcus, et al.
Publicado: (2009)

Hypercompact CRISPR–Cas12j2 (CasΦ) enables genome editing, gene activation, and epigenome editing in plants
por: Liu, Shishi, et al.
Publicado: (2022)

Human cardiac cis-regulatory elements, their cognate transcription factors, and regulatory DNA sequence variants
por: Lee, Dongwon, et al.
Publicado: (2018)

Targeted DNA demethylation of the Fgf21 promoter by CRISPR/dCas9-mediated epigenome editing
por: Hanzawa, Nozomi, et al.
Publicado: (2020)

EpiCas-DL: Predicting sgRNA activity for CRISPR-mediated epigenome editing by deep learning
por: Yang, Qianqian, et al.
Publicado: (2022)

Interactions of Chromatin Context, Binding Site Sequence Content, and Sequence Evolution in Stress-Induced p53 Occupancy and Transactivation
por: Su, Dan, et al.
Publicado: (2015)

Chemical and Light Inducible Epigenome Editing
por: Zhao, Weiye, et al.
Publicado: (2020)

Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells
por: Okada, Masahiro, et al.
Publicado: (2017)

Overcoming the Limitations of CRISPR-Cas9 Systems in Saccharomyces cerevisiae: Off-Target Effects, Epigenome, and Mitochondrial Editing
por: Sato, Genki, et al.
Publicado: (2023)

RTEL1 is required for silencing and epigenome stability
por: Olivier, Margaux, et al.
Publicado: (2023)

Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing
por: Zhou, Hao, et al.
Publicado: (2022)

An enhanced CRISPR repressor for targeted mammalian gene regulation
por: Yeo, Nan Cher, et al.
Publicado: (2018)

Synthetic immunomodulation with a CRISPR super-repressor in vivo
por: Moghadam, Farzaneh, et al.
Publicado: (2020)

Crystal structure of the anti-CRISPR repressor Aca2
por: Usher, Ben, et al.
Publicado: (2021)

Erythroid lineage chromatin accessibility maps facilitate identification and validation of NFIX as a fetal hemoglobin repressor
por: Chaand, Mudit, et al.
Publicado: (2023)

Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here
por: Hermel, Melody, et al.
Publicado: (2023)

CRISPR/Cas9 Gene Editing of NtAITRs, a Family of Transcription Repressor Genes, Leads to Enhanced Drought Tolerance in Tobacco
por: Li, Guimin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a8jpab6f193lr16gjsu071a6ho